Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Pfizer lowers revenue...

    Pfizer lowers revenue forecast on strong dollar, supply issues

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2018-10-31T17:15:16+05:30  |  Updated On 17 Aug 2021 11:44 AM IST

    U.S. drugmaker Pfizer Inc cut the top end of its full-year revenue forecast range on Tuesday, citing a stronger dollar and lower revenue from its sterile-injections business.


    The outlook muddied the largest U.S. drugmaker's better-than-expected third-quarter profit on the back of strong sales of pneumonia vaccine Prevnar.

    Pfizer has been tackling supply shortage issues at its sterile injectable products unit for at least a year. It acquired the business as part of its 2015 purchase of Hospira Inc for $15 billion.

    The company said it now expects full-year revenue between $53.0 billion and $53.7 billion, compared with its previous forecast of $53 billion to $55 billion.

    In the third quarter, Prevnar brought in sales of $1.66 billion compared with $1.52 billion, according to Refinitiv data.

    Cancer drug Ibrance brought in revenue of $1.03 billion, below the average analyst estimate of $1.07 billion.

    The drugmaker has been streamlining operations and investing in its cancer drug portfolio as it prepares for new Chief Executive Albert Bourla to take office next year.

    Excluding special items, the company earned 78 cents per share, beating analysts' average estimate of 75 cents.

    The company's net income rose 45 per cent to $4.11 billion in the three months ended Sept. 30.

    Revenue climbed nearly 1 per cent to $13.30 billion.

    The U.S. drugmaker's shares were down 1.1 per cent at $42.74 before the bell.
    Albert Bourlacancercancer drug IbranceHospira IncPfizerpneumonia vaccine PrevnarUSUS drugmaker Pfizervaccine
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok